Overexpression of cyclin D1 is associated with poor survival in epithelial ovarian cancer

Federica Barbieri, Paola Lorenzi, Nicola Ragni, Gennaro Schettini, Cristina Bruzzo, Francesco Pedullà, Angela Alama

Research output: Contribution to journalArticlepeer-review


Objective: In order to assess the prognostic role of the cell-cycle regulator cyclin D1 in epithelial ovarian cancer, 70 patients have been studied during an observation period of 8 years. Methods: The cyclin D1 protein content was analyzed by Western blotting, and classed as negative, positive and highly positive by densitometric scanning. The relationship between cyclin D1 expression and clinicopathological variables was determined. Univariate and multivariate survival analyses were also carried out. Results: Patients with highly positive cyclin D1 tumors had shorter overall survival than patients with positive cyclin D1 (median survival 31 vs. 49 months; p = 0.058). Furthermore, in patients with stage III/IV tumors and residual disease greater than 2 cm, cyclin D1 expression significantly influenced clinical outcome (p = 0.047 and 0.040, respectively). In the Cox's regression model, cyclin D1 expression and residual disease were identified as the most important predictors of survival (p = 0.016 and 0.002, respectively). In patients with high cyclin D1 expression and residual disease after debulking surgery greater than 2 cm, the relative risks of death were to 2.48 and 3.7, respectively, compared to their correspondent counterparts. Conclusion: The overexpression of cyclin D1 is significantly related to a more aggressive tumor phenotype and poor prognosis in ovarian carcinoma.

Original languageEnglish
Pages (from-to)310-315
Number of pages6
Issue number4
Publication statusPublished - 2004


  • Cyclin D1
  • Ovarian carcinoma
  • Prognostic factor
  • Survival
  • Western blot

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Overexpression of cyclin D1 is associated with poor survival in epithelial ovarian cancer'. Together they form a unique fingerprint.

Cite this